MYC and neoplasm: Certainly, preclinical studies utilizing CX-5461 indicate that targeting ribosome biogenesis will be most efficacious in tumours with dysregulated growth control downstream of the v-myc avian myelocytomatosis viral oncogene homolog (MYC) and PI3K nodes [96,105] and potentially deregulated DNA damage response (DDR) [107].